"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Report Overview
2. CUTANEOUS LUPUS ERYTHEMATOSUS - Overview
3. Executive Summary
4. Cutaneous Lupus Erythematosus: Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. Cutaneous Lupus Erythematosus: Company & Drug Profiles
5.1. Clinical Stage
5.1.1. BIIB059 - Biogen
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. VIB7734 – Viela Bio
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. Tofacitinib citrate – Tufts Medical Center
5.1.3.1. Company Overview
5.1.3.2. Product Description
5.1.3.3. R&D Status & Development Activities
5.1.3.4. Mechanism of Action
5.1.3.5. Molecule Type
5.1.3.6. Stage of Development
5.1.3.7. Indications
5.1.3.8. Route of Administration
5.1.3.9. Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. CUTANEOUS LUPUS ERYTHEMATOSUS: An Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. CUTANEOUS LUPUS ERYTHEMATOSUS: Additional Key Insights
7.1. Epidemiology Overview: CUTANEOUS LUPUS ERYTHEMATOSUS
7.2. Current Market Scenario: Cutaneous Lupus Erythematosus Therapeutics
8. CUTANEOUS LUPUS ERYTHEMATOSUS: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.